-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Blood products are special drugs made from healthy human plasma as raw materials, and biologically active preparations prepared by biological processes or separation and purification technologies; the products mainly include human albumin, specific immunoglobulins and various factor produc.
As blood products play an irreplaceable and important role in medical rescue and the prevention and treatment of certain specific diseases, it is generally believed in the industry that, driven by favorable policies and external mergers and acquisitions, the concentration of blood products industry will increase significant.
Its investment value will also increase simultaneous.
It is understood that, in fact, in recent years, blood products, as the basic medicine for the prevention and control of major diseases and the treatment of critically ill patients, have continued to drive the steady growth of the industry market with the increasing demand, the launch of new products and new indications, and the beginning of the indust.
For example, on the domestic side, the blood products market has started to grow steadily with the increasing demand, the introduction of new products and new indicatio.
Since 2016, China's blood products industry has entered a period of rapid developme.
According to data, the overall market size of the domestic blood products industry has grown from RMB 15 billion in 2016 to about RMB 35 billion in 201Due to the impact of the epidemic, the market size of blood products is still expandi.
However, it is worth noting that because blood products have both resource attributes and policy barrier resource attributes, and in recent years, the country's newly approved plasma stations have become increasingly strict, and the scale effect of blood products has become more and more obvious, and the industry concentration is also increasi.
boo.
It is reported that as of May 2020, there are 30 blood product manufacturers in China that have passed GMP certification; but so far, large blood product companies have greatly increased the concentration of China's blood products industry through mergers and acquisitions; It has formed a situation in which large blood product companies such as Tiantan Bio, Shanghai RAAS, Hualan Bio, and Taibang Bio are the industry leade.
Among them, Tiantan Bio, Hualan Bio, Shanghai RAAS and Taibang Bio, the four leading companies have accounted for more than 60% of the total industry, and the number of pulp stations accounted for more than 5
In addition to the powerhouse occupying most of the market, mergers and consolidations across the industry are becoming more freque.
For example, in November last year, Boya Bio released the "Announcement on the Completion of the Share Agreement Transfer and the Issue of Shares to Specific Objects and the Change of Controlling Shareholders and Actual Controller.
The announcement shows that on November 17, the company has received the "Confirmation Letter of Acceptance of Share Registration Application" issued by China Clearing Corporation Shenzhen Bran.
The company has completed the registration of 78,308,575 A-share ordinary shares issued to China Resources Pharmaceutical Holdin.
At present, the company has registered with Shenzhen Stock Exchan.
Application for listing of new shar.
Industry analysts believe that joining Boya Bio will not only benefit Boya Bio, but also will be an important move for China Resources Pharma to complete the puzzle and make up for shortcomin.
It is worth noting that Boya Bio, which has high expectations from China Resources, has indeed delivered a bright answer in the blood products busine.
The annual report shows that Boya Bio’s blood products business achieved operating income of 232 billion yuan last year, a year-on-year increase of 39
The net profit was 395 million yuan, a substantial increase of 1245% year-on-year, which was mainly due to a combination of factors such as the increase in sales, the increase in the proportion of sales of high-margin varieties, and the increase in corporate wealth management inco.
Industry analysts believe that judging from the market performance of the blood products sector in recent years, the overall performance of the sector is relatively go.
Taking into account the long-term unbalanced supply and demand pattern of the blood product industry, the market pattern of giant competition, and the current situation that China's leading blood product leaders still lag significantly behind international giants, the industry expects that the domestic blood product industry will continue to increase in the context of continuous improveme.
The huge development space may bring more layout opportunities to medium and long-term investo.
However, it should be noted that in the future competition between blood product companies, in addition to the availability of raw plasma, there is also the plasma utilization ra.
The level of plasma utilization depends on the R&D capability and technological level of the enterprise, and requires continuous high investme.
Therefore, in the future, the investment of related enterprises in R&D and expansion of production capacity may continue to increa.
It is understood that for the future business plan, Boya Bio said that in 2022, the company will accelerate the integration with China Resources Pharma in the blood product business, strengthen the expansion of plasma station resources, merge and integrate blood product companies, and expand production capaci.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
As blood products play an irreplaceable and important role in medical rescue and the prevention and treatment of certain specific diseases, it is generally believed in the industry that, driven by favorable policies and external mergers and acquisitions, the concentration of blood products industry will increase significant.
Its investment value will also increase simultaneous.
It is understood that, in fact, in recent years, blood products, as the basic medicine for the prevention and control of major diseases and the treatment of critically ill patients, have continued to drive the steady growth of the industry market with the increasing demand, the launch of new products and new indications, and the beginning of the indust.
For example, on the domestic side, the blood products market has started to grow steadily with the increasing demand, the introduction of new products and new indicatio.
Since 2016, China's blood products industry has entered a period of rapid developme.
According to data, the overall market size of the domestic blood products industry has grown from RMB 15 billion in 2016 to about RMB 35 billion in 201Due to the impact of the epidemic, the market size of blood products is still expandi.
However, it is worth noting that because blood products have both resource attributes and policy barrier resource attributes, and in recent years, the country's newly approved plasma stations have become increasingly strict, and the scale effect of blood products has become more and more obvious, and the industry concentration is also increasi.
boo.
It is reported that as of May 2020, there are 30 blood product manufacturers in China that have passed GMP certification; but so far, large blood product companies have greatly increased the concentration of China's blood products industry through mergers and acquisitions; It has formed a situation in which large blood product companies such as Tiantan Bio, Shanghai RAAS, Hualan Bio, and Taibang Bio are the industry leade.
Among them, Tiantan Bio, Hualan Bio, Shanghai RAAS and Taibang Bio, the four leading companies have accounted for more than 60% of the total industry, and the number of pulp stations accounted for more than 5
In addition to the powerhouse occupying most of the market, mergers and consolidations across the industry are becoming more freque.
For example, in November last year, Boya Bio released the "Announcement on the Completion of the Share Agreement Transfer and the Issue of Shares to Specific Objects and the Change of Controlling Shareholders and Actual Controller.
The announcement shows that on November 17, the company has received the "Confirmation Letter of Acceptance of Share Registration Application" issued by China Clearing Corporation Shenzhen Bran.
The company has completed the registration of 78,308,575 A-share ordinary shares issued to China Resources Pharmaceutical Holdin.
At present, the company has registered with Shenzhen Stock Exchan.
Application for listing of new shar.
Industry analysts believe that joining Boya Bio will not only benefit Boya Bio, but also will be an important move for China Resources Pharma to complete the puzzle and make up for shortcomin.
It is worth noting that Boya Bio, which has high expectations from China Resources, has indeed delivered a bright answer in the blood products busine.
The annual report shows that Boya Bio’s blood products business achieved operating income of 232 billion yuan last year, a year-on-year increase of 39
The net profit was 395 million yuan, a substantial increase of 1245% year-on-year, which was mainly due to a combination of factors such as the increase in sales, the increase in the proportion of sales of high-margin varieties, and the increase in corporate wealth management inco.
Industry analysts believe that judging from the market performance of the blood products sector in recent years, the overall performance of the sector is relatively go.
Taking into account the long-term unbalanced supply and demand pattern of the blood product industry, the market pattern of giant competition, and the current situation that China's leading blood product leaders still lag significantly behind international giants, the industry expects that the domestic blood product industry will continue to increase in the context of continuous improveme.
The huge development space may bring more layout opportunities to medium and long-term investo.
However, it should be noted that in the future competition between blood product companies, in addition to the availability of raw plasma, there is also the plasma utilization ra.
The level of plasma utilization depends on the R&D capability and technological level of the enterprise, and requires continuous high investme.
Therefore, in the future, the investment of related enterprises in R&D and expansion of production capacity may continue to increa.
It is understood that for the future business plan, Boya Bio said that in 2022, the company will accelerate the integration with China Resources Pharma in the blood product business, strengthen the expansion of plasma station resources, merge and integrate blood product companies, and expand production capaci.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
